How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

593 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov

2014 Clinical Trials

122. This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer.

This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer. A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) antiandrogen, non-steroidal androgen) for prostate cancer. Participants who have not undergone surgical castration. Participants with serum testosterone at screening greater than (>) 150 nanogram per deciliter (ng/dL). Participants meeting either of the following criteria for prostate-specific antigen (PSA) at screening. Untreated prostate cancer: PSA at screening > 4.0 nanogram per milliliter (ng/mL) Treated* prostate cancer: PSA at screening > 0.2 ng/mL. Participants who have undergone prostatectomy

2014 Clinical Trials

123. Clinical efficacy of a cosmetic treatment by Crescina(®) human follicle stem cell on healthy males with androgenetic alopecia. (PubMed)

Clinical efficacy of a cosmetic treatment by Crescina(®) human follicle stem cell on healthy males with androgenetic alopecia. Androgenetic alopecia (AGA) is the most common cause of hair loss among males, characterized by progressive thinning of the scalp hairs and defined by various patterns. The main factors underling hair loss in AGA are genetic predisposition and increased sensitivity of the hair follicles to androgens, leading to a shortening of the anagen phase. In the present study (...) , the authors investigated the efficacy of a commercially available cosmetic lotion, Crescina(®) HFSC (human follicle stem cell; Labo Cosprophar AG, Basel, Switzerland), in promoting hair growth and in decreasing hair loss.A placebo-controlled, randomized trial was carried out on healthy males suffering from alopecia grade II to IV. Anagen rate and hair resistance to traction (pull test) were assessed after 2 and 4 months of treatment using phototricogram and pull test technique.Crescina(®) HFSC applied

Full Text available with Trip Pro

2013 Dermatology and therapy

124. Androgenetic Alopecia: Identification of Four Genetic Risk Loci and Evidence for the Contribution of WNT Signaling to Its Etiology. (PubMed)

Androgenetic Alopecia: Identification of Four Genetic Risk Loci and Evidence for the Contribution of WNT Signaling to Its Etiology. The pathogenesis of androgenetic alopecia (AGA, male-pattern baldness) is driven by androgens, and genetic predisposition is the major prerequisite. Candidate gene and genome-wide association studies have reported that single-nucleotide polymorphisms (SNPs) at eight different genomic loci are associated with AGA development. However, a significant fraction

Full Text available with Trip Pro

2013 Journal of Investigative Dermatology

125. Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia

Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Sexual Function (...) in Men Receiving Dutasteride for Androgenetic Alopecia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02014584 Recruitment Status : Completed First Posted : December 18, 2013 Results First Posted : March 8, 2017 Last Update Posted : October 11, 2018 Sponsor: Stiefel, a GSK Company Collaborator

2013 Clinical Trials

126. Health status, coping strategies, and alexithymia in subjects with androgenetic alopecia: a questionnaire study. (PubMed)

Health status, coping strategies, and alexithymia in subjects with androgenetic alopecia: a questionnaire study. Androgenic alopecia (AGA) is viewed as a relatively mild dermatologic condition; however, affected individuals feel that alopecia is a serious condition with major consequences in their life.The objective of this study was to assess the health status, the risk of anxiety/depression, the coping strategies, and alexithymia in subjects with AGA.Consecutive subjects referred (...) their alopecia than to the objective clinical rating. Avoidant coping strategies were selected more frequently by AGA subjects if they were GHQ-12 positive and had alexithymia. To have alexithymia modified all coping strategies in AGA female subjects but not in AGA male subjects. Physicians should be aware that the impact of AGA is not limited to symptoms, and should help people to deal with their emotional responses to alopecia, such as anger and worry, and their beliefs about the consequences

2013 American journal of clinical dermatology

127. Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia

National University Yangsan Hospital Study Details Study Description Go to Brief Summary: Androgenic alopecia is the most common cause of hair loss in men. Finasteride and minoxidil are available in treatment of androgenetic alopecia, although the former causes decreased libido or ejaculate volume, erectile dysfunction, the latter causes scaling, itching of the scalp. Recently, Pulpkin Seed Oil shows some improved clinical efficacy on scalp hair growth in men with androgenetic alopecia (...) , but there is no evidence to support this. The investigators conducted a randomized, double-blind, placebo-controlled efficacy and tolerability trial of Pumpkin seed oil (400mg/day)therapy in male patients with androgenetic alopecia. Condition or disease Intervention/treatment Phase Androgenic Alopecia Dietary Supplement: 400mg /day during 6 months Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 80 participants Allocation: Randomized

2013 Clinical Trials

128. A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia

a global photograph from an earlier assessment (i.e., a withdrawal visit), then that photograph was assessed during the panel review. Number of Participants With the Indicated Change From Baseline (BL) in the Stage of Androgenic Alopecia (AGA) According to the Norwood-Hamilton Scale at 26 Weeks and 52 Weeks [ Time Frame: Baseline, Week 26 and Week 52 ] The investigator/designee assessed the stage (Stage I to Stage VII) of AGA (i.e., male pattern baldness [MPB]) by utilizing the Norwood-Hamilton scale (...) A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2013 Clinical Trials

129. Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis. (PubMed)

Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis. Androgenetic alopecia (AGA) is a genetically determined skin condition strongly age dependent and androgens are assumed to play an important role in its development. A link between AGA and prostate cancer has been hypothesized because of their similar risk factors.We sought to systematically review the evidence available on the association between AGA and risk of prostate cancer.We searched the electronic

2013 Journal of the American Academy of Dermatology

130. Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

25, 2013 Last Update Posted : June 25, 2013 Sponsor: Biotechnology Institute IMASD Information provided by (Responsible Party): Biotechnology Institute IMASD Study Details Study Description Go to Brief Summary: Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals. This clinical trial was designed to evaluate the efficacy and safety of using a preparation (...) Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2013 Clinical Trials

131. Androgen Excess (Follow-up)

Metab . 1961 Nov. 21:1440-7. . Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol . 2003 Nov. 149(5):439-42. . Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol . 1987. 67(2):175-7. . Franks S. Polycystic ovary syndrome. N Engl J Med . 1995 Sep 28. 333(13):853-61. . Azziz R, Carmina E, Dewailly D, Diamanti (...) Androgen Excess (Follow-up) Androgen Excess Follow-up: Further Outpatient Care, Prognosis Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjczMTUzLWZvbGxvd3Vw processing > Androgen Excess Follow-up Updated: Mar 14

2014 eMedicine.com

132. Androgen Excess (Overview)

. . Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol . 2003 Nov. 149(5):439-42. . Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol . 1987. 67(2):175-7. . Franks S. Polycystic ovary syndrome. N Engl J Med . 1995 Sep 28. 333(13):853-61. . Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF (...) Androgen Excess (Overview) Androgen Excess: Practice Essentials, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjczMTUzLW92ZXJ2aWV3 processing > Androgen Excess Updated: Mar 14, 2018

2014 eMedicine.com

133. Androgen Excess (Diagnosis)

. . Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol . 2003 Nov. 149(5):439-42. . Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol . 1987. 67(2):175-7. . Franks S. Polycystic ovary syndrome. N Engl J Med . 1995 Sep 28. 333(13):853-61. . Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF (...) Androgen Excess (Diagnosis) Androgen Excess: Practice Essentials, Pathophysiology, Epidemiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjczMTUzLW92ZXJ2aWV3 processing > Androgen Excess Updated: Mar 14

2014 eMedicine.com

134. Androgen Excess (Treatment)

. . Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol . 2003 Nov. 149(5):439-42. . Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol . 1987. 67(2):175-7. . Franks S. Polycystic ovary syndrome. N Engl J Med . 1995 Sep 28. 333(13):853-61. . Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF (...) Androgen Excess (Treatment) Androgen Excess Treatment & Management: Medical Care, Surgical Care, Consultations Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjczMTUzLXRyZWF0bWVudA== processing > Androgen Excess

2014 eMedicine.com

135. Age dependent associations between androgenetic alopecia and prostate cancer risk. (PubMed)

Age dependent associations between androgenetic alopecia and prostate cancer risk. Both prostate cancer and androgenetic alopecia are strongly age-related conditions that are considered to be androgen dependent, but studies of the relationship between them have yielded inconsistent results. We aimed to assess whether androgenetic alopecia at ages 20 and 40 years are associated with risk of prostate cancer.At a follow-up of the Melbourne Collaborative Cohort Study, men were asked to assess (...) their hair pattern at ages 20 and 40 years relative to eight categories in showcards. Cases were men notified to the Victorian Cancer Registry with prostate cancer diagnosed between cohort enrollment (1990-1994) and follow-up attendance (2003-2009). Flexible parametric survival models were used to estimate age-varying HRs and predicted cumulative probabilities of prostate cancer by androgenetic alopecia categories.Of 9,448 men that attended follow-up and provided data on androgenetic alopecia, we

Full Text available with Trip Pro

2012 Cancer Epidemiology & Biomarkers and Prevention

136. Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients

Alopecia (female pattern hair loss) Exclusion Criteria: patients with alopecia areata or cicatricial alopecia pregnancy and breastfeeding have undergone any specific treatment in the last 06 months use of drugs with anti-androgenic properties patients with signs or symptoms of hyper-androgynism Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided (...) Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2012 Clinical Trials

137. The contribution of endogenous and exogenous factors to female alopecia: a study of identical twins. (PubMed)

The contribution of endogenous and exogenous factors to female alopecia: a study of identical twins. In this study, the authors investigated the potential contribution of environmental factors and testosterone levels on androgenic alopecia in women.Ninety-eight identical female twins were recruited from 2009 to 2011. Subjects were asked to complete a comprehensive questionnaire, provide a sputum sample for testosterone analysis, and pose for standardized digital photography. Frontal, temporal (...) (p = 0.048), and lack of exercise (p = 0.012) were associated with increased vertex hair loss. Higher testosterone levels were associated with increased temporal and vertex hair loss patterns (p < 0.039). Increased stress, increased smoking, having more children, and having a history of hypertension and cancer were all associated with increased hair thinning (p < 0.05).This study implicates several environmental risk factors in the pathophysiology of female alopecia.

2012 Plastic and reconstructive surgery

138. Androgenic alopecia

Androgenic alopecia Pattern hair loss - Wikipedia Pattern hair loss From Wikipedia, the free encyclopedia (Redirected from ) Pattern hair loss Other names Androgenic alopecia, androgenetic alopecia, male pattern baldness, female androgenic alopecia, female pattern baldness Male-pattern hair loss , Pattern hair loss , known as male-pattern hair loss ( MPHL ) when it affects males and female-pattern hair loss ( FPHL ) when it affects females, is that primarily affects the top and front (...) of 50 affects about half of males and a quarter of females. It is the most common cause of . Contents Signs and symptoms [ ] Classic male-pattern hair loss begins above the and vertex ( ) of the . As it progresses, a rim of hair at the sides and rear of the head remains. This has been referred to as a 'Hippocratic wreath', and rarely progresses to complete baldness. Pattern hair loss is classified as a form of non-scarring hair loss. The has been developed to grade androgenic alopecia in males

2012 Wikipedia

139. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. (PubMed)

Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. The role of genetic predisposition and the influence of sex steroid hormones are indisputable to the pathogenesis of male androgenetic alopecia (MAGA). The role of sex steroid hormones in female pattern hair loss (FPHL) is less known. A good knowledge of the pathophysiology underlying MAGA and FPHL empowers the clinician to confidently counsel patients and make (...) informed therapeutic decisions. Vigorous research in recent years has provided greater insight into the role of genetics and sex steroids in physiological hair growth and cycling, as well as in hair follicle miniaturization, the histological hallmark of MAGA and FPHL. In the present review article directed towards clinicians, we discuss the current understanding of the role of androgens and oestrogens, as well as genetic associations with MAGA and FPHL. We also briefly discuss the interpretation

2011 Australasian Journal of Dermatology

140. Androgenetic Alopecia in Fabry Disease

is to assess whether patients with the classic form of Fabry disease have significantly less androgenic alopecia (male pattern baldness). Condition or disease Fabry Disease Detailed Description: Objectives: To test the hypothesis that adult males with classic form of Fabry disease have a significantly lower incidence of androgenic alopecia than matched controls. Study Population: 120 patients aged 20-64 with Fabry disease that have GLA mutations or alpha-galactosidase A activity associated with no residual (...) enzyme activity and non-Fabry male controls of the same age range and the same number of non-Fabry controls. Design: This is a cross-sectional study comparing the prevalence of androgenic alopecia in two groups of subjects. Outcome Measures: The levels of the outcome will be no androgenic alopecia and frontal only androgenetic alopecia opposed to vertex only and frontal and vertex androgenetic alopecia. Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>